Ignyta is a biotechnology company catalyzing personalized medicine in autoimmune diseases.
Acquired by Roche
Ignyta is a scientifically-driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goal is to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease
targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide.
Ignyta was incorporated in 2011 and operates in San Diego, California.